About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Monte Rosa Therapeutics, Inc. (GLUE): Insider Trades and Fund Holdings
In the past 12 months, Monte Rosa Therapeutics, Inc. insiders reported no open-market purchases and 13 sales worth $2.05M; 10 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Oct 5, 2026Insider salePrincipal Accounting Officer Matthew Bowen sold $137
- Jul 16, 2026Insider saleCEO Markus Warmuth sold $220,219
- Jul 15, 2026Insider saleCOO Jennifer Champoux sold $101,730 under a 10b5-1 plan
- Jul 6, 2026Insider saleChief Scientific Officer Sharon Townson sold $139,849 under a 10b5-1 plan
- Jun 30, 2026Insider saleChief Medical Officer Filip Janku sold $132,472 under a 10b5-1 plan
- Jun 30, 2026FundDuquesne Family Office opened a position in Q2 2026 (13F filed Aug 14, 2026)
- Jun 30, 2026FundRenaissance Technologies cut 73% in Q2 2026 (13F filed Aug 13, 2026)
- Jun 29, 2026Insider saleDirector Anthony M. Manning sold $231,100
- Jun 29, 2026Insider saleChief Medical Officer Filip Janku sold $137,700 under a 10b5-1 plan
- Jun 24, 2026Insider saleChief Medical Officer Filip Janku sold $642,681 under a 10b5-1 plan
- Jun 23, 2026Insider saleChief Medical Officer Filip Janku sold $239,522 under a 10b5-1 plan
- Jun 23, 2026Insider saleChief Scientific Officer Sharon Townson sold $60,000 under a 10b5-1 plan
- Jun 23, 2026Insider saleCOO Jennifer Champoux sold $43,500 under a 10b5-1 plan
- Jun 17, 2026Insider saleChief Scientific Officer Sharon Townson sold $57,000 under a 10b5-1 plan
- Jun 17, 2026Insider saleCOO Jennifer Champoux sold $41,344 under a 10b5-1 plan
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 6, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 6 | Matthew BowenPrincipal Accounting Officer | ▼ SELL | $137 |
| Jul 17 | Markus WarmuthCEO | ▼ SELL | $220K |
| Jul 16 | Jennifer ChampouxCOO | ▼ SELL10b5-1 | $102K |
| Jul 7 | Sharon TownsonChief Scientific Officer | ▼ SELL10b5-1 | $140K |
| Jul 1 | Filip JankuChief Medical Officer | ▼ SELL10b5-1 | $132K |
| Jun 30 | Anthony M. ManningDirector | ▼ SELL | $231K |
| Jun 30 | Filip JankuChief Medical Officer | ▼ SELL10b5-1 | $138K |
| Jun 25 | Filip JankuChief Medical Officer | ▼ SELL10b5-1 | $643K |
| Jun 25 | Filip JankuChief Medical Officer | ▼ SELL10b5-1 | $240K |
| Jun 25 | Sharon TownsonChief Scientific Officer | ▼ SELL10b5-1 | $60K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Matthew Bowen | Principal Accounting Officer | 0 | $0 | 1 | $137 |
| Markus Warmuth | CEO | 0 | $0 | 1 | $220K |
| Jennifer Champoux | COO | 0 | $0 | 3 | $187K |
| Sharon Townson | Chief Scientific Officer | 0 | $0 | 3 | $257K |
| Filip Janku | Chief Medical Officer | 0 | $0 | 4 | $1.15M |
| Anthony M. Manning | Director | 0 | $0 | 1 | $231K |
A All 13 insider trades reported on time. How it is graded
Tracked funds that report GLUE
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 102,500 | $2.48M | ▼ −73.0% |
| Duquesne Family Office | 297,600 | $7K | ▲ New |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →